ArticleiScience2026
Novel plasma protein signatures for early diagnosis and prognostic stratification in colorectal cancer.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) remains a major global health concern, underscoring the need for reliable biomarkers for diagnosis and prognosis. In this study, untargeted plasma proteomics was conducted across two cohorts comprising 321 participants in the discovery set and 353 in the validation set. Machine learning methods were employed to select biomarkers and develop diagnostic and prognostic models, with performance evaluated by the area under the receiver operating characteristic curve (AUC). An eight-protein panel for CRC and a six-protein panel for advanced adenoma discriminated from healthy controls with AUCs of 0.932 and 0.816 in the validation set, respectively. Additionally, a combined prognostic model incorporating eight proteins and clinical factors predicted 5-year disease-free survival in CRC with an AUC of 0.744 in the validation cohort. Overall, the identified protein biomarkers have the potential to foster the development of effective blood-based tests for early detection and prognostic prediction of CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.